Dimethyl Fumarate Capsule, Delayed Release
Product Images NDC 84677-029

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Dimethyl Fumarate (NDC 84677-029). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

84677-029-14 (Dimethyl Fumarate 120 mg REV 0626.jpg)

84677-029-14 (Dimethyl Fumarate 120 mg REV 0626.jpg)
Label for Dimethyl Fumarate delayed-release capsules, 120 mg strength, manufactured by Golden State Medical Supply, Inc. The label indicates a bottle containing 14 capsules and includes usage instructions, storage conditions, and a barcode. The product is prescription-only and dispensed in original packaging.*
FDA Label Image

84677-030-60 (Dimethyl Fumarate 240mg REV 0626.jpg)

84677-030-60 (Dimethyl Fumarate 240mg REV 0626.jpg)
Dimethyl Fumarate 240 mg delayed-release capsules label for oral use. The label shows a package containing 60 capsules, marked Rx only, from Golden State Medical Supply, Inc. It includes instructions to dispense in the original package and swallow capsules whole. The label also identifies the product as made in India and marketed by GSMS, Incorporated in Camarillo, CA.*
FDA Label Image

Figure 1: Time To 12-week Confirmed Progression Of Disability (study 1) (Dimethyl Fig1)

Figure 1: Time To 12-week Confirmed Progression Of Disability (study 1) (Dimethyl Fig1)
A line graph comparing the percentage of subjects with confirmed progression of disability over time in weeks during a study. The graph features two groups: one receiving placebo and the other receiving Dimethyl Fumarate Delayed-Release Capsules 240 mg BID. The placebo group shows a higher percentage progression (27.1%) at week 96 compared to 16.4% in the Dimethyl Fumarate group.*
FDA Label Image

Dimethyl-str (Dimethyl Str)

Dimethyl-str (Dimethyl Str)
Chemical structure of dimethyl fumarate showing the molecular arrangement of atoms and bonds typical for this compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.